@JesperGunst profile picture
Jesper D. Gunst @JesperGunst

MD PhD working on clinical trials in #HIV using #bNAbs, #LRAs and/or #TLR agonists.

Joined April 2017
  • Tweets 117
  • Following 102
  • Followers 102
3 Photos and videos
Jesper D. Gunst retweeted
Christian Gaebler@c_gaebler
24 Oct 2024
🚨 We’re hiring! 🚨 Join the Gaebler & Ibrahim Labs for an exciting postdoc position at the intersection of virology & gene regulation! Help us uncover mechanisms behind HIV latency using cutting-edge genome engineering. More info: nature.com/naturecareers/job…

Postdoctoral Scientist (d/f/m) in Life Sciences/Genetics - Berlin (DE)

The mission of the Berlin Institute of Health at Charité (BIH) is medical translation: transferring biomedical research findings into novel approac...

nature.com
7
10
1,995
Jesper D. Gunst retweeted
EACS@EACSociety
24 Jul 2024
Exciting news! Our survey report with @ECDC_EU on #HIV #stigma in the #healthcare setting is now available. Huge thanks to everyone who contributed to its success! 👉bit.ly/46kI1uN Don't miss the presentation on Friday by @TeyNoori at #AIDS2024
11
13
3,342
Jesper D. Gunst retweeted
Ming Lee@jnim87
23 Jul 2024
Vibeke Klastrup presenting metanalysis of ATI studies showing smaller reservoir size and interventions such as #bNAbs are associated with duration of viral control during treatment interruptions. #AIDS2024
1
1
183
Jesper D. Gunst retweeted
Oana Sandulescu@sandulescu_oana
14 Jun 2024
How to interpret and how to manage low level viremia? Hearing now from @JesperGunst with important insight from amazing session chair @Rokx1 at #YINGconf24
1
2
6
281
Jesper D. Gunst retweeted
Jillian Lau@JillianLau1
4 Mar 2024
Onto my fave topic - analytical treatment interruptions: where ART is stopped in an #HIVcure study. Viral rebound. Tongcui Ma showed T cell features (pic 1) and Mauro Garcia showed IgG antibodies (pic 2) impacted time to viral rebound. Use as biomarkers for TVR? #CROI2024
1
3
12
1,430
Jesper D. Gunst retweeted
EACS@EACSociety
30 Nov 2023
The survey on "Measuring #HIV knowledge and attitudes in the #healthcare setting" is still available until 5 Dec! Complete it today or spread the word in your network. 🔄 Available in 38 languages! 🌍 Survey link: ow.ly/w7vH50QcPWv @ECDC_EU
11
14
1,441
Jesper D. Gunst retweeted
NEJM Evidence@NEJMEvidence
14 Nov 2023
Editorial: “Host Receptor Targeting to Treat #Covid19” by @JesperGunst and Ole Schmeltz Søgaard eviden.cc/3ScIr1C #SARSCov2 #InfectiousDisease @AarhusUni_int @AUHdk @syctong @Josh_S_Davis @jasonroberts_pk

Host Receptor Targeting to Treat Covid-19

nejm.org
2
4
1,422
Jesper D. Gunst retweeted
EATG@EATGx
10 Nov 2023
If you work in a healthcare setting in Europe or Central Asia, you are invited to take this survey on stigma & discrimination by @ECDC_EU and @EACSociety ⏲️ Deadline: 30 November 2023 #StigmaFree
Teymur Noori@TeyNoori
19 Oct 2023
Replying to @ECDC_EU
@ECDC_EU & @EACSociety are measuring HIV knowledge and attitudes in healthcare settings across Europe and Central Asia. Please help promote the survey which can be found here in 38 languages: eacsociety.org/activities/ea… Deadline is 30 November. 🙏 @EATGx @aidsactioneurop @WHO_Europe
5
5
554
Jesper D. Gunst retweeted
NEJM Evidence@NEJMEvidence
2 Nov 2023
Inhibition of intracellular enzymes like TMPRSS2 that are vital for replication of #SARSCoV2 may be an effective treatment strategy for #COVID19. Gunst and Sogaard comment on recent clinical evidence for the effect of TMPRSS2 inhibitors like nafamostat. eviden.cc/3ScIr1C
4
12
21,706
Jesper D. Gunst retweeted
Christian Gaebler@c_gaebler
12 Oct 2023
Exciting news! The Berlin Institute of Health at Charité @berlinnovation is launching its BIH PhD Program, focused on medical translation and innovation. 🌟 Fully funded doctoral positions for translational projects 🌟 Open for applications until Nov 22 bihealth.org/en/notices/bih-…
2
8
2,352
European AIDS Clinical Society (EACS) vil undersøge viden og holdninger om HIV blandt sundhedsfaglige på tværs af Europa. Så hvis du har ca. 10 min til at udfylde - vil vi blive glade! @Sygeplejeraadet @laegeforeningen @Sundpol @regionerne eacsociety.org/activities/ea…

1
2
103
@ECDC_EU @ECDC_HIVAIDS @EACSociety
1
1
89
Jesper D. Gunst retweeted
Nature Medicine
@NatureMedicine
27 Sep 2023
In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 nature.com/articles/s41591-0…

1
2
9
6,048
Review on Immunomodulation with IL-7 and IL-15 in #HIV-1 infection. @viruseradicate sciencedirect.com/science/ar…
3
10
568
Jesper D. Gunst retweeted
HIV cure@HIVcureAU
21 Sep 2023
Results from the Titan Study show promise that broadly neutralising antibodies (BNABS) are a component of a future HIV Cure. hivcure.com.au/2023/09/13/bn…

bNABs as a component of an HIV cure - HIV Cure

Treating HIV involves daily treatment for life. The TITAN study investigated a strategy using bNABs, towards an HIV cure

hivcure.com.au
4
17
39
8,435
Results from the TITAN trial is out. First of all, a huge thanks to the participants and their families for investing in these trials. Ongiong 🧵 below..
Nature Medicine
@NatureMedicine
13 Sep 2023
In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 nature.com/articles/s41591-0…
8
5
13
1,935
#TITAN #HIV #HIVcure #bNAbs #TLR Funding by @GileadSciences
258
Lastly, thanks to all our collaborators. My mentor: @ole_s_sogaard @AUHdk @HealthAarhusUni @AarhusUni_int @NussenzweigL @AwesomeJonesLab @AlfredHealth @TheDohertyInst @DAREtoCureHIV @Oslounivsykehus @UniOslo @AalborgUH @OUHhospital @AmagerHvidovre @Rigshospitalet @RHGoedstrup
80
No added benefit of combining lefitolimod with bNAbs compared to bNAbs alone. The bNAbs are doing something and support further investigation as part of curative strategies. Additionally, we need better assays for bNAb prediction.
72
No strong evidence of a bNAb-mediated vaccinal effect on HIV-1-specific CD8 T cell response.
74
During the early phase of ATI, bNAbs prevented HIV reservoir expansion, whereas non-bNAb recipients had expansion of their reservoir.
67
Load more